Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models.

Buffa V, Stieh D, Mamhood N, Hu Q, Fletcher P, Shattock RJ.

J Gen Virol. 2009 Jan;90(Pt 1):234-43. doi: 10.1099/vir.0.004358-0.

PMID:
19088294
2.

Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249.

Veazey RS, Ketas TA, Klasse PJ, Davison DK, Singletary M, Green LC, Greenberg ML, Moore JP.

Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10531-6. doi: 10.1073/pnas.0802666105. Epub 2008 Jul 22.

3.

Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study.

McCormick AA, Reddy S, Reinl SJ, Cameron TI, Czerwinkski DK, Vojdani F, Hanley KM, Garger SJ, White EL, Novak J, Barrett J, Holtz RB, Tusé D, Levy R.

Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10131-6. doi: 10.1073/pnas.0803636105. Epub 2008 Jul 21.

4.

Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent.

Huskens D, Vermeire K, Vandemeulebroucke E, Balzarini J, Schols D.

Int J Biochem Cell Biol. 2008;40(12):2802-14. doi: 10.1016/j.biocel.2008.05.023. Epub 2008 Jun 11.

PMID:
18598778
5.

Setting the stage: host invasion by HIV.

Hladik F, McElrath MJ.

Nat Rev Immunol. 2008 Jun;8(6):447-57. doi: 10.1038/nri2302. Review.

6.

Cost-effective production of a vaginal protein microbicide to prevent HIV transmission.

Ramessar K, Rademacher T, Sack M, Stadlmann J, Platis D, Stiegler G, Labrou N, Altmann F, Ma J, Stöger E, Capell T, Christou P.

Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3727-32. doi: 10.1073/pnas.0708841104. Epub 2008 Mar 3.

7.

Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission.

Klasse PJ, Shattock R, Moore JP.

Annu Rev Med. 2008;59:455-71. Review.

PMID:
17892435
8.

Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide.

Emau P, Tian B, O'keefe BR, Mori T, McMahon JB, Palmer KE, Jiang Y, Bekele G, Tsai CC.

J Med Primatol. 2007 Aug;36(4-5):244-53.

PMID:
17669213
9.

HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.

Blish CA, Nedellec R, Mandaliya K, Mosier DE, Overbaugh J.

AIDS. 2007 Mar 30;21(6):693-702.

PMID:
17413690
10.

Crystallographic, thermodynamic, and molecular modeling studies of the mode of binding of oligosaccharides to the potent antiviral protein griffithsin.

Ziółkowska NE, Shenoy SR, O'Keefe BR, McMahon JB, Palmer KE, Dwek RA, Wormald MR, Wlodawer A.

Proteins. 2007 May 15;67(3):661-70.

PMID:
17340634
11.

Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1.

Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, Eschenbach D, McElrath MJ.

Immunity. 2007 Feb;26(2):257-70.

12.

Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.

Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM, Li Y, Salazar MG, Polonis VR, Mlisana K, Karim SA, Hong K, Greene KM, Bilska M, Zhou J, Allen S, Chomba E, Mulenga J, Vwalika C, Gao F, Zhang M, Korber BT, Hunter E, Hahn BH, Montefiori DC.

J Virol. 2006 Dec;80(23):11776-90. Epub 2006 Sep 13.

13.

Domain-swapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate binding.

Ziółkowska NE, O'Keefe BR, Mori T, Zhu C, Giomarelli B, Vojdani F, Palmer KE, McMahon JB, Wlodawer A.

Structure. 2006 Jul;14(7):1127-35.

14.

In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories.

Beer BE, Doncel GF, Krebs FC, Shattock RJ, Fletcher PS, Buckheit RW Jr, Watson K, Dezzutti CS, Cummins JE, Bromley E, Richardson-Harman N, Pallansch LA, Lackman-Smith C, Osterling C, Mankowski M, Miller SR, Catalone BJ, Welsh PA, Howett MK, Wigdahl B, Turpin JA, Reichelderfer P.

Antimicrob Agents Chemother. 2006 Feb;50(2):713-23.

15.

Transgenic plant production of Cyanovirin-N, an HIV microbicide.

Sexton A, Drake PM, Mahmood N, Harman SJ, Shattock RJ, Ma JK.

FASEB J. 2006 Feb;20(2):356-8. Epub 2005 Dec 14.

PMID:
16354721
16.

Recombinant production of anti-HIV protein, griffithsin, by auto-induction in a fermentor culture.

Giomarelli B, Schumacher KM, Taylor TE, Sowder RC 2nd, Hartley JL, McMahon JB, Mori T.

Protein Expr Purif. 2006 May;47(1):194-202. Epub 2005 Nov 7.

PMID:
16300962
17.

Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion.

Veazey RS, Klasse PJ, Schader SM, Hu Q, Ketas TJ, Lu M, Marx PA, Dufour J, Colonno RJ, Shattock RJ, Springer MS, Moore JP.

Nature. 2005 Nov 3;438(7064):99-102. Epub 2005 Oct 30.

PMID:
16258536
18.

Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12.

Calarese DA, Lee HK, Huang CY, Best MD, Astronomo RD, Stanfield RL, Katinger H, Burton DR, Wong CH, Wilson IA.

Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13372-7. Epub 2005 Sep 7.

19.
20.

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.

Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC.

J Virol. 2005 Aug;79(16):10108-25.

Supplemental Content

Support Center